Living Cell Technologies is engaged in the clinical development of cell based therapeutics for the treatment of diabetes and pre-clinical research and development into neurological disorders predominantly in New Zealand. The Company's business is focused on the discovery and advancement of products through preclinical and early clinical development. The Company has two therapeutic candidates in clinical development: DIABECELL®, which is in late-stage clinical trials for the treatment of type 1 diabetes; and NTCELL®, which is in Phase I clinical trials for the treatment of Parkinson's disease.Data provided by Mergent, Inc.
|Effective Date||Jul 17, 2007|
|Industry||Pharma. & Biotech.|